Avience Biomedicals (NSE:AVIENCE) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
18 GF Score
Price ₹250.90
! 3 Warning Signs
View Full Analysis

What is Avience Biomedicals 3-Year EBITDA Growth Rate?

Avience Biomedicals NSE:AVIENCE +1.17% 18 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 144508.53% on this metric.

Avience Biomedicals's EBITDA per Share for the six months ended in Mar. 2025 was ₹21.95.

During the past 12 months, Avience Biomedicals's average EBITDA Per Share Growth Rate was 170.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Avience Biomedicals  (NSE:AVIENCE) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Avience Biomedicals 3-Year EBITDA Growth Rate Related Terms

NSE:AVIENCE vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Avience Biomedicals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avience Biomedicals 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Avience Biomedicals's 3-Year EBITDA Growth Rate falls into.


NSE:AVIENCE
18GF Score
Avience Biomedicals Ltd NSE:AVIENCE
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Avience Biomedicals (NSE:AVIENCE) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avience Biomedicals and its competitors. According to the industry distribution chart, Avience Biomedicals ranks #999999 out of 692 companies in the Medical Devices & Instruments industry.
Is Avience Biomedicals' 3-Year EBITDA Growth Rate too high?
Avience Biomedicals' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Avience Biomedicals ranks #999999 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #999999 out of 692 companies for 3-Year EBITDA Growth Rate. This places Avience Biomedicals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score

Get the complete analysis for NSE:AVIENCE

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹250.90
Price